Parkinson
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Parkinson is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- AbbVie wins FDA nod for Parkinson’s disease drug · European Medical Journal · 2026-09-29
- AbbVie's Once-Daily Parkinson's Pill Juvmo Wins FDA Approval, with Nausea, Dizziness, and Headache Common in Trials · Medical Daily · 2026-09-28
- AstronauTx Receives Michael J. Fox Foundation Funding for Parkinson’s Research · Pulse 2.0 · 2026-09-25
- Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy · GEN - Genetic Engineering & Biotechnology News · 2026-09-19
- Son who used AI to help save mum's life hopes case unlocks clues for other Parkinson's patients · BBC News — UK · 2026-10-01 · usually covers UK Economy
- US FDA Approves AbbVie’s Once-Daily Parkinson’s Disease Drug Tavapadon · Voice of Healthcare · 2026-09-29 · usually covers Precision Medicine
What the reporting says
Across 81 tracked stories from 45 outlets, reporting on Parkinson most often describes regulatory approvals (9), launches or releases (4), public statements (3), meetings or visits (2), award (2), acquisition (2).
It shows up alongside Alzheimer (25), FDA (20), AI (19), China (14), United Kingdom (13), Clinical Trial (9), Cros (9), Genetic Engineering (8).
Two steps out: Cder (through FDA, 20 shared stories on the weaker link); Congress (through FDA, 20 shared stories on the weaker link); Drug Administration (through FDA, 20 shared stories on the weaker link); Drug Development (through FDA, 20 shared stories on the weaker link).
Tracked since May 16, with coverage on 29 separate days — concentrated in Auto.